secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001641172-25-013711
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 preclinical study in Werner Syndrome model shows 100% survival, reverses epigenetic aging
--------------------------------------------------------------------------------

- Oral Telomir-1 restored healthy DNA methylation at two CpG island regions, resetting the epigenetic clock.
- Telomere length increased beyond levels seen in healthy controls.
- Full reversal of muscle and body weight loss in the Werner Syndrome animal model.
- 100% survival in Telomir-1-treated animals vs 15% mortality in untreated controls.
- Oxidative stress markers reduced by up to 50%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225013711/0001641172-25-013711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225013711/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer